Sun Pharma Advanced Research Company Ltd. (SPARC) announced on Tuesday that the US Food and Drug Administration (USFDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) linked to the approval of its neonatal seizure therapy Sezaby. According to reports from Moneycontrol, PRVs are tradable vouchers issued by the USFDA to incentivize development of treatments for rare pediatric conditions, and can be redeemed to secure a priority review for a separate, future drug application—often shaving months off the review clock for high-value assets. As per latest reports, the PRV is specifically associated with the approval of Sezaby®, with SPARC describing it as a benzyl alcohol- and propylene glycol–free formulation of phenobarbital sodium powder for injection for the treatment of neonatal seizures.
SPARC stated it intends to use the voucher to 'further accelerate' its pipeline, signaling it may either deploy the PRV internally for a key program or potentially monetize it depending on strategic needs. As reported by Moneycontrol, CEO Anil Raghavan described receiving the Priority Review Voucher as a 'significant milestone for SPARC' and testament to the company's commitment to addressing urgent, unmet patient needs. The award recognizes both the therapeutic value of Sezaby and provides SPARC with additional strategic flexibility to accelerate pipeline development to bring more therapies to patients faster.
Market analysts suggest SPARC could monetize the PRV to clean up its balance sheet, including debt of around ₹400 crores, with the voucher potentially fetching at least ₹100 million. According to market reports, this compares favorably to the ₹200 million transaction by Jazz Pharma in January this year, which was valued at ₹1,800 crores. Additionally, SPARC has a ₹600 crore warrant that would get approved on the 8th this month with an immediate cash infusion of ₹150 crores. These transactions are expected to change the balance sheet and risk landscape of the company in a very positive manner.
Following the announcement, SPARC shares rose 6 percent and were trading at ₹139.50 on BSE on Tuesday at 10:30 am, as reported by Moneycontrol. The stock demonstrated strong intraday performance with a high of ₹148.10 and low of ₹137.40, with 321,913 shares traded across 3,282 trades and a net turnover of ₹459.56 crore. The positive market reaction reflects investor confidence in the strategic value of the USFDA priority review voucher and its potential to accelerate future drug development programs.
